Maximus, Inc. (MMS) Rating Lowered to Sell at Zacks Investment Research
Maximus, Inc. (NYSE:MMS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.
According to Zacks, “MAXIMUS, Inc. is an extremely dynamic and complex organization that offers government and industry a range of unique services, products, and solutions. The diverse services and products that MAXIMUS offers may be categorized into three groups: Government Program Management and Operations, Consulting, and Systems. Government Program Management and Operations focuses on having a measurable impact on the lives of the citizens we help government serve. The insights of MAXIMUS Consulting, and the technological innovations advanced through Systems, help government gain program efficiencies and pursue improvements that in turn benefit citizens. “
Several other analysts also recently issued reports on the company. BidaskClub downgraded Maximus from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. Canaccord Genuity downgraded Maximus from a “buy” rating to a “hold” rating and set a $62.00 price objective on the stock. in a report on Tuesday, July 4th. KeyCorp restated a “sector weight” rating on shares of Maximus in a report on Thursday, May 25th. ValuEngine downgraded Maximus from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th. Finally, Jefferies Group LLC downgraded Maximus from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $63.00 to $64.00 in a report on Friday, May 5th. One analyst has rated the stock with a sell rating and eight have given a hold rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $61.00.
Shares of Maximus (NYSE:MMS) opened at 60.61 on Tuesday. The stock’s 50 day moving average is $62.52 and its 200-day moving average is $60.48. The stock has a market capitalization of $3.93 billion, a P/E ratio of 19.87 and a beta of 1.40. Maximus has a one year low of $43.69 and a one year high of $64.97.
Maximus (NYSE:MMS) last posted its quarterly earnings data on Thursday, May 4th. The health services provider reported $0.80 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.02. The firm had revenue of $622 million for the quarter, compared to the consensus estimate of $620.24 million. Maximus had a return on equity of 26.21% and a net margin of 8.18%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.74 EPS. On average, equities research analysts expect that Maximus will post $3.05 EPS for the current year.
WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/07/20/maximus-inc-mms-rating-lowered-to-sell-at-zacks-investment-research.html.
In other news, CEO Richard A. Montoni sold 30,000 shares of the company’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $62.81, for a total value of $1,884,300.00. Following the transaction, the chief executive officer now owns 584,114 shares in the company, valued at approximately $36,688,200.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel David Francis sold 1,000 shares of the company’s stock in a transaction dated Friday, July 14th. The shares were sold at an average price of $60.46, for a total value of $60,460.00. Following the completion of the transaction, the general counsel now owns 15,715 shares in the company, valued at approximately $950,128.90. The disclosure for this sale can be found here. Insiders sold a total of 109,846 shares of company stock worth $6,893,986 in the last quarter. 3.10% of the stock is owned by corporate insiders.
Several large investors have recently made changes to their positions in the stock. Neuburgh Advisers LLC boosted its stake in shares of Maximus by 1.9% in the first quarter. Neuburgh Advisers LLC now owns 1,696 shares of the health services provider’s stock valued at $105,000 after buying an additional 32 shares during the last quarter. Acrospire Investment Management LLC boosted its stake in shares of Maximus by 183.3% in the first quarter. Acrospire Investment Management LLC now owns 1,700 shares of the health services provider’s stock valued at $106,000 after buying an additional 1,100 shares during the last quarter. Glen Harbor Capital Management LLC boosted its stake in shares of Maximus by 1.9% in the first quarter. Glen Harbor Capital Management LLC now owns 2,332 shares of the health services provider’s stock valued at $145,000 after buying an additional 44 shares during the last quarter. Elkfork Partners LLC boosted its stake in shares of Maximus by 1.9% in the first quarter. Elkfork Partners LLC now owns 2,968 shares of the health services provider’s stock valued at $185,000 after buying an additional 56 shares during the last quarter. Finally, Violich Capital Management Inc. purchased a new stake in shares of Maximus during the first quarter valued at approximately $217,000. 98.03% of the stock is owned by institutional investors and hedge funds.
Maximus Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Receive News & Stock Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related stocks with our FREE daily email newsletter.